Maternal immunization: understanding safety and efficacy and making a strong recommendation

Lakshmi Sukumaran, MD, MPH
Medical Officer, Immunization Safety Office

Ashley Brooks, MPH
Health Communication Specialist
National Center for Immunization and Respiratory Diseases

ACOG/ACNM Maternal Immunization Webinar
March 1, 2018
ACCME Accreditation
The American College of Obstetricians and Gynecologists is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA PRA Category 1 Credit(s)™
The American College of Obstetricians and Gynecologists designates this *enduring material* for a maximum of 1 *AMA PRA Category 1 Credit™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

College Cognate Credit(s)
The American College of Obstetricians and Gynecologists designates this *enduring material* for a maximum of 1 Category 1 College Cognate Credit. The College has a reciprocity agreement with the AMA that allows *AMA PRA Category 1 Credits™* to be equivalent to College Cognate Credits.

Disclosure of Faculty and Industry Relationships
In accordance with the College policy, all faculty and planning committee members have signed a conflict of interest statement in which they have disclosed any financial interests or other relationships with industry relative to topics they will discuss at this program. At the beginning of the program, faculty members are expected to disclose any such information to participants. Such disclosure allows you to evaluate better the objectivity of the information presented in lectures. Please report on your evaluation form any undisclosed conflict of interest you perceive. Thank you!
This webinar was made possible by cooperative agreement number 6 5 NU38OT000161-05-00 from the Centers for Disease Control and Prevention (CDC) and the Association of State and Territorial Health Officials (ASTHO). Its contents are solely the responsibility of ACOG and do not necessarily represent the official views of CDC or ASTHO.
Our recommended software and hardware configuration is the following:

**Windows**

- Processor: 850MHz or faster processor (or above)
- Memory: 512MB of RAM (or above)
- Screen Resolution: 1024 x 768 (or above)
- Microsoft Internet Explorer 5.5 (or higher)
- or Mozilla Firefox 1.5
- Adobe Flash Player 8 (or higher)
- Adobe Acrobat 6 (or higher)

**Macintosh**

- Processor: G3 500MHz or faster processor (or above)
- Operating System: OS 10.3 (or above)
- Memory: 512MB of RAM (or above)
- Screen Resolution: 1024 x 768 (or above)
- Mozilla Firefox 1.5 or Safari 1.2.2 browser supported for Mac OS X 10.3 or higher
- Adobe Flash Player 8 (or higher)
- Adobe Acrobat 6 (or higher)
CONFLICT OF INTEREST DISCLOSURE: FACULTY/PLANNING COMMITTEE/REVIEWER/STAFF

Kevin A. Ault, MD – Research: Inovio and NIH; Consultant: ACI Clinical, Moderna Therapeutics, NIH, CDC, and ACOG; Data and Safety Monitoring Board: NIH, CDC and Novartis

Brenna L. Hughes, MD – Royalties from UpToDate for authorship; Scientific Advisory: Merck

Flor Munoz, MD – Author and Editorial Board: UpToDate; DSMB Member: Moderna, NIH, Propel study, Thrasher; Research (CTA trough Baylor College of Medicine): Biocryst, Alios, Regeneron, Novavax, CDC respiratory and GI viral surveillance, The National Institutes of Health, BMGF - GAIA project - Vaccine safety; Advisory board: WHO - maternal immunization with influenza/GBS projects

Laura E. Riley, MD – Author: UpToDate; Published Author: Wiley Publishing

Geeta K. Swamy, MD – Research: GSK, Novavax, Regeneron; Independent Data Monitoring Committee: GSK; Chairperson, External Data Monitoring Committee: Pfizer

All other faculty, planning committee members, reviewers and staff have no conflict of interest to disclose relative to the content of the presentation.
Course Faculty

Lakshmi Sukumaran, MD, MPH
Medical Officer, Immunization Safety Office
Centers for Disease Control and Prevention

Ashley Brooks, MPH
Health Communication Specialist
National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention
Learning Objectives

• Discuss the scientific evidence supporting maternal flu vaccination safety and monitoring.
• Educate pregnant patients about the importance of an annual flu vaccine.
• Name three components of a strong recommendation.
• Use CDC ACOG, ACNM and messaging and resources to address patient questions and concerns regarding flu immunization.
Disclaimer

- The findings and conclusions in this presentation are those of the author and do not necessarily represent the official position of the CDC
56 deaths among US pregnant women
38-Day-Old Baby Dies After Persisting Cough

By LARA SALAH • April 28, 2010

Whooping Cough Epidemic Rages in California: 5 Babies Dead, 910 Infected

Five babies dead from whooping cough so far this year in biggest outbreak for 20 years

Newborn Nearly Dies Contracting Whooping Cough

Whooping Cough Back Again With A Vengeance In California

Third baby dies from whooping cough in California

Disease burden highest in infants during pertussis epidemic

10 infants dead in California whooping cough outbreak
OVERVIEW

- Infections and vaccinations during pregnancy
- CDC vaccine safety monitoring in pregnancy
- Results of inactivated influenza vaccine (IIV) and tetanus, diphtheria, and acellular pertussis (Tdap) safety studies in pregnancy
- Maternal vaccine safety recap
Vaccination during pregnancy protects mom and baby
Infections in pregnant women and neonates

- Maternal influenza
  - Physiologic changes during pregnancy → severe disease\(^1\)
  - 5-fold increased risk of death in pregnant women (typically 2\(^{nd}\)/3\(^{rd}\) trimester)

- Neonatal influenza
  - No infant vaccine until 6 months of age
  - Infants at high risk of hospitalization and death from influenza\(^2\)

- Neonatal pertussis
  - Primary immunization series complete at 6 months
  - Majority of pertussis deaths occur in infants < 3 months of age\(^3\)

---

Increased susceptibility to severe influenza infection

<table>
<thead>
<tr>
<th>First trimester</th>
<th>Second trimester</th>
<th>Third trimester</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monocytes and phagocytosis</td>
<td>Polymorphonuclear cells</td>
<td>α-Defensins</td>
</tr>
<tr>
<td>Dendritic cells</td>
<td></td>
<td>Regulatory T cells</td>
</tr>
<tr>
<td>CD4+ T cells</td>
<td>CD8+ T cells</td>
<td>B cells</td>
</tr>
<tr>
<td>CD4+ T cells</td>
<td></td>
<td>Natural killer cells</td>
</tr>
<tr>
<td>CD8+ T cells</td>
<td></td>
<td>Cytotoxicity</td>
</tr>
</tbody>
</table>

Potential impacts of exposures during pregnancy

- **Pre-implantation (0-2 weeks)**: Injury to a large number of cells → spontaneous abortion

- **Embryonic period (2-9 weeks)**: Major defects and altered function of organs

- **Fetal period (9 weeks - term)**: Small for gestational age, intrauterine growth restriction, fetal death, minor malformations, altered function of organs

Recommendations for influenza vaccine during pregnancy

- Advisory Committee on Immunization Practices (ACIP) recommendations for pregnant women
  - 1960: Pregnant women noted to be at risk of severe illness and were recommended to receive influenza vaccine
  - since 1990s: Vaccination during 2nd and 3rd trimesters recommended
  - 2004: Influenza vaccine recommended for all pregnant women during any trimester of pregnancy
  - 2017: Any licensed, recommended and age-appropriate trivalent, quadrivalent, or recombinant inactivated influenza vaccine can be administered during pregnancy

Recommendations for Tdap vaccine during pregnancy

- ACIP recommendations in pregnant women\(^1\)
  - 2006: Tdap booster to post-partum mothers and family members (cocooning)
  - 2011: Tdap for unvaccinated pregnant women after 20 weeks gestation
  - 2012: Tdap for every pregnant woman at every pregnancy regardless of prior immunization status (optimally between 27-36 weeks gestation)
CDC prioritizes maternal vaccine safety
Vaccine licensure process in the United States

Why post-licensure vaccine safety monitoring?

- Pregnant women often excluded from pre-licensure clinical trials
- Pre-licensure clinical trials may not detect rare events
- Safety standards for vaccines are high
CDC vaccine safety monitoring

1 office

VAERS

Immunization Safety Office

CISA

VSD

3 core programs

VAERS: Vaccine Adverse Event Reporting System, VSD: Vaccine Safety Datalink, CISA: Clinical Immunization Safety Assessment
CDC vaccine safety monitoring

VAERS
Vaccine Adverse Event Reporting System

Co-managed by CDC and FDA
CDC vaccine safety monitoring

VSD
Vaccine Safety Datalink

8 participating healthcare organizations
Identifying pregnancies in the VSD

- VSD uses an validated algorithm\(^1\) to identify pregnancy outcomes and start and end dates from electronic health records
- VSD data can be used to link pregnant women to their children
- VSD annual cohort ~3% of US population\(^2\)
  - ~125,000 pregnancies per year
  - ~90,000 live births per year
- Additional pregnancy data: Height and weight, education, prior pregnancy history, smoking and alcohol use, plurality, delivery type, Apgars, last menstrual period, estimated due date

CISA
Clinical Immunization Safety Assessment

7 participating healthcare organizations

- assist U.S. healthcare providers with complex vaccine safety questions about their patients
- conduct clinical research

vaccine safety experts
Influenza vaccine safety studies: mom, baby and pregnancy
Maternal influenza studies – general safety

- IIV and live attenuated influenza vaccines during pregnancy in VAERS, 1990-2009\(^1\)
  - No unusual patterns of pregnancy complications or fetal outcomes
- Influenza A (H1N1) 2009 monovalent vaccine during pregnancy in VAERS\(^2\)
  - No concerning patterns of maternal or fetal outcomes
- IIV during pregnancy in VAERS, 2010-2016\(^3\)
  - No vaccine safety concerns among pregnant women or their infants

Maternal influenza studies – maternal outcomes

- Medically attended maternal acute events in the VSD\textsuperscript{1,2}
  - Outcomes included allergic reactions, local reactions, neurologic events
  - No increased risk following IIV or monovalent H1N1 vaccines
- Feasibility of text message influenza vaccine safety monitoring during pregnancy\textsuperscript{3,4}
  - Prospective CISA study
  - Post-vaccination fever was infrequent and a typical pattern of maternal and neonatal health outcomes was observed

\textsuperscript{1} Nordin JD et al. Vaccine (2014)
\textsuperscript{2} Nordin JD et al. Obstet Gynecol (2013)
\textsuperscript{3} Stockwell M et al. AJPM (2017)
\textsuperscript{4} Registered at ClinicalTrials.gov \url{www.clinicaltrials.gov} (NCT01974050)
Maternal influenza studies – pregnancy outcomes

- Spontaneous abortion (SAB) in the VSD\(^{1,2}\)
  - No increased risk of SAB in the 28 days following IIV exposure during 2005-2007 influenza seasons\(^1\)
  - Increased risk of SAB in the 28 days following IIV exposure during 2010-2012 influenza seasons\(^2\)
    - Risk seen in women vaccinated in prior influenza season
  - Follow up study evaluating subsequent influenza seasons in progress

Maternal influenza studies – pregnancy outcomes

- Medically attended adverse obstetric events in the VSD$^{1,2}$
  - Outcomes included hyperemesis, gestational hypertension, gestational diabetes, proteinuria, urinary tract infection
  - No increased risk following IIV or monovalent H1N1 vaccines

- Adverse birth outcomes in the VSD$^3$
  - No increased risk of preterm birth or small for gestational age following IIV

Maternal influenza studies – infant outcomes

- Major birth defects after vaccination in VAERS, 1990 to 2014\(^1\)
  - Major birth defects were infrequently reported, with no condition reported disproportionally

- Major structural birth defects in the VSD\(^2\)
  - No increased risk after first trimester IIV exposure

- Infant mortality and hospitalizations in the VSD\(^3\)
  - No increased risk of infant death, hospitalization or hospitalizations from respiratory causes following maternal IIV exposure

Systematic reviews and meta-analyses

- Outcomes: fetal death, spontaneous abortion, congenital malformations\(^1\)
  - In 19 studies, no increased risk of fetal death, spontaneous abortion, or congenital malformation following influenza vaccine
- Outcomes: stillbirth and spontaneous abortion\(^2\)
  - In 7 studies, lower risk of stillbirth and no increased risk of spontaneous abortion following influenza vaccine
- Outcome: congenital malformations\(^3\)
  - In 15 studies, no association was found between congenital defects and influenza vaccination at any trimester or at first trimester

---

A word about thimerosal

- Currently only used in multi-dose vials of influenza vaccine
- Institute of Medicine: “Immunization safety review: vaccines and autism”¹
  - Scientific evidence does not support a causal association between thimerosal-containing vaccines and autism
- CDC study: “Prenatal and infant exposure to thimerosal from vaccines and immunoglobulins and risk of autism” ²
  - Case-control study in VSD found prenatal exposure to thimerosal containing immunizations did not increase the risk of autism

Tdap vaccine safety studies: mom, baby and pregnancy
Maternal Tdap studies – general safety

- Adverse events after Tdap vaccines in pregnant women in VAERS, 2005-2010
  - During a time when Tdap was not routinely recommended in pregnancy, no concerning patterns in maternal, infant, or fetal outcomes

- Enhanced surveillance of Tdap vaccines in pregnancy in VAERS, 2011-2015
  - No new or unexpected adverse events were noted among vaccinated pregnant women after routine recommendations for maternal Tdap vaccination
  - Changes in reporting patterns expected, given the broader use of Tdap in pregnant women in the third trimester

Maternal Tdap studies – maternal outcomes

- Medically attended maternal acute adverse events in the VSD\textsuperscript{1-3}
  - Outcomes included local reactions, allergic reactions, neurologic events
  - No increased risk following Tdap vaccine, concomitant Tdap and IIV, or following repeated doses of tetanus-containing vaccines

- Clinical study of Tdap safety in pregnant women in CISA (in progress)\textsuperscript{4,5}
  - Prospective observational study in pregnant and non-pregnant women
  - Preliminary findings: Tdap was well tolerated and immunogenic; proportion of reactions in pregnant women receiving repeat Tdap not higher than those receiving first Tdap

4. Presented to ACIP June 2016
5. Registered at ClinicalTrials.gov \url{www.clinicaltrials.gov NCT02209623}
Maternal Tdap studies – pregnancy outcomes

- Adverse obstetric events in the VSD\(^1\)
  - Small statistically significant increased risk of chorioamnionitis
    - Follow-up study evaluating infant morbidity showed no signals (next slide)
    - No increased risk of hypertensive disorders of pregnancy
- Chorioamnionitis reports to VAERS\(^2\)
  - Chorioamnionitis was infrequently reported (<1% of pregnancy reports) over a period of 24 years\(^2\)
- Adverse birth outcomes in the VSD\(^1,3,4\)
  - No increased risk of preterm delivery, small for gestational age following Tdap vaccine, concomitant Tdap and IIV, or following repeated doses of tetanus-containing vaccines

Maternal Tdap studies – infant outcomes

- Birth defects in the VSD\(^1\)
  - No increased risk of microcephaly or other structural birth defects
    - Response to concerns of increase in microcephaly in Brazil related to Zika

- Infant morbidity in the VSD\(^2\)
  - No increased risk of tachypnea of newborn, neonatal sepsis, neonatal pneumonia, respiratory distress syndrome, newborn convulsions after maternal Tdap vaccine despite slight increase in diagnosed chorioamnionitis

- Infant mortality and hospitalizations in the VSD\(^3\)
  - No increased risk for infant death, hospitalizations or respiratory hospitalizations after maternal Tdap

1. DeSilva M et al. JAMA (2016)
Maternal vaccine safety recap
Recap

- Pregnant women and neonates at increased risk of complications from influenza and pertussis disease
  - Vaccination during pregnancy important tool to protect pregnant women and their infants
- Pregnant women often excluded from drug and vaccine pre-licensure trials
  - Post-licensure monitoring crucial
- The CDC has a comprehensive mechanism for monitoring vaccine safety
  - Studies support the use of influenza and Tdap vaccines in pregnancy and are consistent with larger body of evidence
Your recommendation matters

- Consistently shown in literature to be the most influential factor in a patient’s decision to receive an immunization
Maternal Immunization: Understanding Safety and Efficacy and Making a Strong Recommendation

Maternal Vaccination Communication Strategies

Ashley Brooks, MPH
Health Communication Specialist
National Center for Immunization and Respiratory Diseases
Overview

- ACIP-recommended immunization schedule for pregnant women
- Research surrounding maternal immunization communication
- Role of health care provider
- Use of CDC, ACOG, and ACNM messaging and resources to address patient questions
ACIP recommendations for pregnant women
# Maternal Vaccination

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Before pregnancy</th>
<th>During pregnancy</th>
<th>After pregnancy</th>
<th>Type of vaccine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Influenza</td>
<td>Yes</td>
<td>Yes, during flu season</td>
<td>Yes</td>
<td>Inactivated</td>
</tr>
<tr>
<td>Tdap</td>
<td>May be recommended; it is better to vaccinate during pregnancy when possible</td>
<td>Yes, during each pregnancy</td>
<td>Yes, immediately postpartum, if Tdap never received in lifetime; it is better to vaccinate during pregnancy</td>
<td>Toxoid/ Inactivated</td>
</tr>
<tr>
<td>Td</td>
<td>May be recommended</td>
<td>May be recommended, but Tdap is preferred</td>
<td>May be recommended</td>
<td>Toxoid</td>
</tr>
<tr>
<td>Hepatitis A</td>
<td>May be recommended</td>
<td>May be recommended</td>
<td>May be recommended</td>
<td>Inactivated</td>
</tr>
<tr>
<td>Hepatitis B</td>
<td>May be recommended</td>
<td>May be recommended</td>
<td>May be recommended</td>
<td>Inactivated</td>
</tr>
<tr>
<td>Meningococcal</td>
<td>May be recommended</td>
<td>Based decision on risk vs. benefit; inadequate data for specific recommendation</td>
<td>May be recommended</td>
<td>Inactivated</td>
</tr>
<tr>
<td>Pneumococcal</td>
<td>May be recommended</td>
<td>Based decision on risk vs. benefit; inadequate data for specific recommendation</td>
<td>May be recommended</td>
<td>Inactivated</td>
</tr>
<tr>
<td>HPV</td>
<td>May be recommended (through 26 years of age)</td>
<td>No</td>
<td>May be recommended (through 26 years of age)</td>
<td>Inactivated</td>
</tr>
<tr>
<td>MMR</td>
<td>May be recommended; once received, avoid conception for 4 weeks</td>
<td>No</td>
<td>May be recommended</td>
<td>Live</td>
</tr>
<tr>
<td>Varicella</td>
<td>May be recommended; once received, avoid conception for 4 weeks</td>
<td>No</td>
<td>May be recommended</td>
<td>Live</td>
</tr>
</tbody>
</table>
Influenza and pregnant women
Health and Economic Cost of Influenza

- Millions of cases per year, varies year to year
- 226,000 hospitalizations per year, >75% among adults
- 3,000–49,000 deaths per year, >90% among adults
- Direct medical cost – $10.4 billion
- With loss of work and life – $87 billion
- Estimates for 2015–2106
  - 25 million illnesses
  - 11 million medical visits
  - 310,000 hospitalizations
  - 12,000 deaths

4. CDC. Estimated Influenza Illnesses, Medical Visits, Hospitalizations, and Deaths Averted by Vaccination in the United States, 2017. Available at: www.cdc.gov/flu/about/disease/2015-16.htm
Influenza and Pregnancy

- Influenza illness during pregnancy
  - Higher risk for severe illness and complications
  - Increase in delivery complications (fetal distress, preterm labor, cesarean delivery)

- Vaccinating pregnant women
  - Protective levels of anti-flu antibody for mom, passive transfer of antibody for baby
  - Reduced risk for influenza infection and hospitalizations among infants <6 mos age
  - 36%↓ in respiratory illness for mom, 29%↓ for infants <6 mos age
  - 63%↓ in lab-confirmed flu among infants <6 mos age

- Influenza vaccination recommended for women who are or will be pregnant
  - CDC, American College of Obstetricians and Gynecologists, American College of Nurse Midwives, American Academy of Family Physicians


- 2012-13: 50.5%
- 2013-14: 52.2%
- 2014-15: 50.3%
- 2015-16: 49.9%
- 2016-17: 53.7%
Maternal Flu Vaccine Recommendation

- CDC recommends that pregnant women get a flu shot during any trimester of their pregnancy to protect themselves and their newborn babies from flu.

- By the end of October, if possible, to help ensure protection before flu activity begins to increase.
Pertussis and pregnant women
Burden of Pertussis

- Notifiable disease based on clinical, lab, epi criteria
- 21,000 cases in 2015, 22% among adults (underdiagnosed and underreported)
- Transmission from adults to children
  - Disease most severe for infants
  - Among hospitalized, apnea (61%), pneumonia (23%), death (1%)

CDC. National Notifiable Disease Surveillance System [www.cdc.gov/pertussis/surv-reporting.html](http://www.cdc.gov/pertussis/surv-reporting.html)
CDC. MMWR 2017;66(11):1-28
Pertussis Vaccination Recommendations

- Adults
  - 1 dose Tdap if previously not received, except for pregnant women

- Pregnant women
  - Direct protection for mom, indirect protection for baby
  - Infants of vaccinated moms were born with significantly higher anti-pertussis antibodies if Tdap given in pregnancy weeks 27–36
  - Concentration of anti-pertussis antibodies in infant cord blood higher when mothers vaccinated earlier in this window
  - Longer exposure to vaccine allows higher vaccine-induced antibody levels produced by mother and transferred to infant
  - Vaccination is recommended for every pregnancy
  - Cocooning alone may not be effective and it is difficult to implement

CDC. MMWR 2012;61:ND:719–32
CDC. MMWR 2013;62(07):131–135
Pertussis Vaccination Recommendations

- **Adults**
  - 1 dose Tdap if previously not received, except for pregnant women

- **Pregnant women**
  - Direct protection for mom, indirect protection for baby
  - Infants of vaccinated moms were born with significantly higher anti-pertussis antibodies if Tdap given in pregnancy weeks 27–36
  - Concentration of anti-pertussis antibodies in infant cord blood higher when mothers vaccinated earlier in this window
  - Longer exposure to vaccine allows higher vaccine-induced antibody levels produced by mother and transferred to infant

Administer 1 dose of Tdap every pregnancy preferably during early part of gestational weeks 27–36

CDC. MMWR 2012;61:ND:719–32
CDC. MMWR 2013;62(07):131–135
Pregnant women should get influenza vaccine and Tdap (for every pregnancy)

But vaccination coverage rates remain low

- We know that health care provider recommendations have big impact
- So, focus on effective messaging and communication strategies
What does communication research tell us?

CDC Maternal Research
Summary of Findings from 2014 Mixed Methods Research

Methodology:
• Surveys
• Focus groups
• In depth interviews

Pregnant Women
• Low disease and vaccine awareness
• Protection for their babies is very important
• Want to be assured of safety
• High information-seeking
• Want information from ob-gyn or midwife

Ob-gyns
• Are recommending vaccines to pregnant patients
• Understand importance of maternal vaccination
• Low perceived susceptibility
• Systems barriers to stocking vaccines
Online survey and message testing with pregnant women
- 251 pregnant women aged 18-45 years in U.S. receiving prenatal care
- Mixed household income, age, and experience with pregnancy
- Range of intention for flu and Tdap vaccines

In-depth interviews with HCPs
- 16 OB-GYNs and 8 certified nurse midwives (CNM)
- Across all regions of U.S.
- Included those that provide Tdap onsite + those that refer

Additional Research: November – December 2016
Key Findings: Pregnant Women

- **Vaccine Recommendations**
  - 69% received flu vaccine recommendation and 41% received Tdap vaccine recommendation
  - About 60% who received recommendations (for flu or Tdap vaccine) were told the vaccine was “extremely or very important”

- **Vaccine Acceptance**
  - More respondents had gotten or intended to get flu vaccine (59%) than Tdap (42%)
  - 28% had decided not to get each of the vaccines

- **Vaccine Decision-making**
  - Pregnant women get vaccines because their prenatal care providers recommend them or because they heard the illnesses could harm their baby.
  - They want information about safety of individual vaccines, side effects, and vaccine ingredients.
How HCPs Talk about Maternal Vaccines

- Most use similar Tdap and flu vaccine messages with patients
- Most discuss Tdap and flu vaccination concurrently, during initial intake visit
  - Use printed materials to help educate patients about vaccines
- Key message themes to facilitate vaccine conversations:
  - Disease susceptibility and severity
  - Vaccination benefits (protection, passive immunity)
  - Vaccine safety
- CNMs were more likely than OB-GYNs to feel uncomfortable making a strong recommendation for either vaccine, as they view it as a patient decision
Best Ways to Reach Pregnant Women

- Pregnant women get maternal vaccination formation from 3 main sources:
  - 80% HCPs (most important source for 60%)
  - 50% Internet health resources
  - 33% Family

- However, most are not actively looking for information about pregnancy vaccines

- Some pregnant women would be prompted by messages they see online to ask their HCP about maternal vaccination
Role of Health Care Provider
We know pregnant women have questions once they realize they need vaccines…

Is it safe for me and my baby?

Can’t I just get it after my baby is born (like my last pregnancy)?

Why every pregnancy?

Why hasn’t my doctor talked to me about this?

Is it enough to just make sure everyone around my baby is vaccinated (or if we stay away from sick people)?

Are these diseases really dangerous?
They may look to many sources for pregnancy-related information
Standards for Adult Immunization Practice

- All health care providers, including those who do not provide vaccine services, have role in ensuring adult patients up-to-date on vaccines

- Call to action for adult health care providers to
  - **ASSESS** vaccination status of all patients at every clinical encounter
  - Strongly **RECOMMEND** vaccines that patients need
  - **ADMINISTER** needed vaccines or **REFER** to a vaccine service provider
  - **DOCUMENT** vaccines received by patients in state vaccine registries

Public Health Reports 2014;129:115–123
Present Vaccination as a Standard Part of Obstetric Care

- Provide your patients with information and resources about maternal vaccines during her first prenatal visit, and be sure to mention the timeframe for each vaccine when discussing her pregnancy
- Ensure your staff deliver consistent messaging about the importance of maternal vaccines
- Normalize vaccination as part of your patients’ pregnancy care
Making a strong recommendation
Vaccination Uptake by Provider Recommendation and Offer

Influenza vaccination coverage before and during pregnancy among women pregnant any time during October 1, 2016 – January 31, 2017 and who visited a health care provider at least once since July 2016, by provider recommendation or offer.

- **71%** offered
- **44%** recommended but not offered
- **15%** no recommendation

97.9% visited health care provider at least once before or during pregnancy

When recommended and offered from obstetric provider, vaccine acceptance 5x to 50x higher

---

1. CDC. Pregnant Women and Flu Vaccination, Internet Panel Survey
Providers should talk to pregnant patients about the importance of **on-time** vaccination

- Pregnant patients need to be vaccinated to protect them and their babies
- Pregnant patients may not be aware of the recommendations
- Healthcare providers are patients most trusted sources of health information during their pregnancies.
Strong Vaccine Recommendation

- CDC’s research indicates that some pregnant women do not feel their healthcare providers strongly recommend vaccines.
- Providers should state clearly that they would like her to get vaccinated.

“Today, I strongly recommend two vaccines to help protect you and your baby against the flu and whooping cough.”
HCPs can SHARE information with patients

- **SHARE** tailored reasons why the recommended vaccine is right for the patient
- **HIGHLIGHT** positive experiences with vaccines to reinforce the benefits and strengthen confidence in vaccination
- **ADDRESS** patient questions and any concerns about the vaccines
- **REMIND** patients about the protection vaccines can help provide from serious diseases
- **EXPLAIN** the potential costs of getting the disease
Resources and Tools
Digital Resources

- Website
- Quiz
- Motion graphic
- Listicle
- Digital Toolkit

www.cdc.gov/vaccines/pregnancy
Print Resources

www.cdc.gov/vaccines/pregnancy
ACOG Resources

- Immunization for Women website
- Patient & Provider Resources:
  - Clinical Guidance
  - FAQs
  - Recommendations
  - Safety
  - Coding and Reimbursement
  - Practice Management
ACNM Resources

- Talking Points
- Position statements
- FAQ
- Posters, coloring books
- Curriculum
- Other resources
- http://midwife.org/Immunization-Resources-for-Providers

- SuperMom
What Can YOU Do?

- **GET VACCINATED**
- **TALK** to pregnant patients about maternal vaccines
  - Tell them why it’s important for them and their babies
  - Make the conversation and recommendation memorable and compelling
- **ADMINISTER** indicated vaccines in your office if possible and **FOLLOW UP** to ensure receipt
- **USE** and **PROMOTE** resources available and encourage others to do the same
  - Include maternal vaccine resources in prenatal information packets
  - Promote resources and products through social media channels
- **EDUCATE** your staff about maternal vaccines
  - Identify or serve as a Vaccine Champion in your practice
- **ENCOURAGE** pregnant women to ask questions
- **TELL US** what else you need to help you communicate about vaccines

[www.cdc.gov/vaccines/pregnancy](http://www.cdc.gov/vaccines/pregnancy)
Contact Information

ACOG

Debra Hawks, MPH
dhawks@acog.org

Sarah Carroll, MPH
scarroll@acog.org

Sarah Wright, MPH
Swright@acog.org

Lindsey Regallis
lregallis@acog.org

ACNM

Elaine Germano, CNM, DrPH, FACNM
eagermano@acnm.org

Carol Hayes, CNM, MN, MPH
carolhayescnm@gmail.com
Questions?

For more information, contact CDC
1-800-CDC-INFO (232-4636)

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

Photographs and images included in this presentation are licensed solely for CDC/NCIRD online and presentation use. No rights are implied or extended for use in printing or any use by other CDC CIOs or any external audiences.
Extra Slides
Spontaneous abortion (SAB) and influenza vaccine

- Background rates of SAB range from 10-22%
- Miscarriages following (not attributed to) influenza vaccine are expected
- Limited data on first trimester influenza vaccine exposure
  - In a 2015 systematic review, 7 studies evaluating SAB found no risk
- Observational studies have limitations
  - Cannot prove flu vaccine was cause of miscarriage
- Original VSD study evaluating 2005-2007 seasons found no risk
  - Follow up study results expected 2019

How to talk to patients about SAB

- Health care decisions should be an ongoing discussion between provider and patient
- Providers should use clinical judgement, based on factors including the patient’s health status, local influenza activity, and then benefits versus potential risks from flu vaccination when deciding whether and/or when to immunize their patient against influenza